Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > ARCHIVE
ARCHIVE
- METIS Inaugurates 3rd-Phase Plan
December 17, 2007
- New Stock Exchange Market NEO to Stimulate Drug Discovery by Bioventures
December 17, 2007
- Medical Devices to Be Re-priced if They Are 1.7 Times More Expensive than Overseas
December 17, 2007
- BUSINESS NEWS IN BRIEF
December 17, 2007
- MEDICAL DEVICE NEWS IN BRIEF
December 17, 2007
- Re-Pricing Runs Counter to Innovation: Industry
December 17, 2007
- TOPICS／Number of Female MRs Increasing but Their Retention Rates Need Improvement
December 17, 2007
- Eisai Submits NDA for KES524 for Obesity
December 10, 2007
- Large Gap between Korosho and Council on Views on Kongo Shinryo
December 10, 2007
- Wyeth Submits 3rd NDA This Year
December 10, 2007
- Korosho to Set Up Group to Discuss Deregulations, Kongo Shinryo
December 10, 2007
- Astellas Aims at Becoming a Global Category Leader
December 10, 2007
- REGULATORY NEWS IN BRIEF
December 10, 2007
- Ban on Kongo Shinryo Should Be Lifted: Prof. Shimada
December 10, 2007
- MEDICAL FACILITIES & NURSING CARE NEWS IN BRIEF
December 10, 2007
- Banyu Conducts PI Study in Japan and South Korea Ahead of US
December 10, 2007
- Revised Osteoporosis GL Discussed at JOS Meeting
December 10, 2007
- Geninax Posts \1.9 Bil. Sales in the 1st Month
December 10, 2007
- Clinical Trial Network Created by Six Universities
December 10, 2007
- Half of Physicians Start Osteoporosis Treatment in Patients with Reduced Bone Mass
December 10, 2007
ページ
Japan’s pharmaceutical policy appears to be entering a new phase. The government’s newly approved honebuto policy and growth strategy both…
A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…